DelMar Pharmaceuticals, Inc. (DMPI) Q3 2019 Earnings Conference Call May 23, 2019 4:30 PM ET Company Participants Saiid Zarrabian - President & Chief Executive Officer Scott Praill - Chief Financial Officer Greg Johnson - Head of Clinical & Operations Conference Call Participants Operator Thank you all for joining us this afternoon for the DelMar Pharmaceuticals Quarterly Call and Webcast to discuss the Company's Financial Results for the Third Quarter of the 2019 Fiscal Year Ending June 30, 2019 and Corpor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________________ Commission file number: 001-37823 DelMar Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | Nevada | 99 ...

Financial Data and Key Metrics Changes - For Q2 2019, the company reported a net loss of approximately $1.8 million or $0.08 per share, compared to a net loss of approximately $3.2 million or $0.14 per share for the same quarter in 2018, indicating an improvement in financial performance [30] - Research and development expenses decreased to approximately $940,000 from approximately $2.1 million year-over-year, primarily due to reduced clinical development costs and personnel expenses [31] - General and administrative expenses also decreased to approximately $875,000 from approximately $1 million year-over-year, largely due to lower professional fees [32] Business Line Data and Key Metrics Changes - The company is focused on advancing VAL-083 through two Phase 2 biomarker-driven clinical trials for MGMT-unmethylated glioblastoma, with significant progress reported in both trials [11][20] - The MD Anderson study has enrolled 46 out of a planned 48 patients, with completion expected soon, while the China study has enrolled 14 out of 30 patients [13][20] Market Data and Key Metrics Changes - The company is targeting the approximately 60% to 66% of newly diagnosed GBM patients with unmethylated MGMT status, who are underserved by current therapies [14] - The ongoing studies are expected to provide data that could inform treatment options for this specific patient population, which has a poor prognosis with existing therapies [14][43] Company Strategy and Development Direction - The company aims to extend its cash resources to support ongoing clinical trials and is optimistic about the potential for VAL-083 to improve overall survival in GBM patients [9][27] - There is a strategic focus on the MGMT-unmethylated population to expedite the approval process for VAL-083, as this group is believed to require fewer patients to demonstrate efficacy [51][56] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the ongoing Phase 2 studies and their potential to mitigate risks associated with NASDAQ compliance [27] - The company is committed to a fiscally responsible approach while exploring additional oncology indications for VAL-083, contingent on the success of current trials [23] Other Important Information - The company received an extension from NASDAQ until June 25, 2019, to regain compliance with the minimum bid price requirement [27] - A recent publication highlighted the unique mechanism of action of VAL-083, suggesting potential for combination therapies in treating other cancers [25] Q&A Session Summary Question: Can you talk about the MDACC study and what can be learned from it? - Management discussed the dosing strategy and the importance of focusing on the MGMT-unmethylated population, which has shown poor responses to current therapies [42][43] Question: How is methylated status determined and what impact could data from China have? - Management confirmed that the testing for methylated status is well-established and that positive data from China could significantly alter treatment expectations for unmethylated GBM patients [48][53] Question: Is the decision to focus on unmethylated GBM patients a business strategy? - Management clarified that the focus on this population is a strategic decision to expedite trials and reduce costs, not a limitation of VAL-083's efficacy [51][56]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2018 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________________ Commission file number: 001-37823 DelMar Pharmaceuticals, Inc. (Exact name of registrant as specified in its cha ...